Open-label PTH(1-84) ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 235 | 副甲状腺機能低下症 | 1 |
235. 副甲状腺機能低下症
臨床試験数 : 88 / 薬物数 : 128 - (DrugBank : 25) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01199614 (ClinicalTrials.gov) | December 2009 | 9/9/2010 | HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism | HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism | Hypoparathyroidism | Drug: open-label PTH(1-84) | John P. Bilezikian | NPS Pharma;Shire | Active, not recruiting | 18 Years | 85 Years | All | 75 | Phase 3 | United States |